Sign Up
Stories
Advancing OSE-279: Promising Cancer Treatment
Share
ABIONYX Pharma Files 2023 Document
AEON Biopharma Advances Migraine Treatme...
AEON Biopharma Advances Migraine Treatme...
AI-Powered Cancer Drug Trials
Aldeyra Therapeutics R&D Day 2024
Aligos Therapeutics Financial Disclosure
Overview
API
OSE Immunotherapeutics reports positive Phase 1/2 results for OSE-279 in advanced solid tumors, showcasing high anti-tumor response rates and safety, leading to expanded clinical development.
Ask a question
How might the success of OSE-279 impact the future landscape of cancer immunotherapy?
In what ways could these positive clinical results influence the approach to treating advanced solid tumors globally?
What challenges or opportunities could arise from combining OSE-279 with other drug candidates?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Nov 2023
Dec 2023
Jan 2024
Coverage